Talk about burying bad news.
At an industry conference last summer, Collegium Pharmaceuticals (COLL) prominently touted the benefits of its Xtampza ER opioid painkiller with a striking display panel at its exhibit booth. The promotional tool sported a well-designed illustration in different colors and font sizes that conveyed an upbeat message for those attending the gathering of the American Society of Health-System Pharmacists in Minneapolis.
But the risks associated with the drug were much harder to notice. Why?
About the Author Reprints
Ed, it’s Xtampza ER, not Xtamza ER. “tamp”, as in hard to tamper with. the blurb in today’s Stat+ email also contains this typo.
It is harder to tamper with than OxyContin, but I guarantee that’s not why some insurers are covering it instead of OxyContin — it’s all about cost despite their attempt to turn it into positive PR.
Thanks, TW. Looks like the ‘p’ was dropped a couple of times. Thanks for noting that.
And I agree with you that the cost is the issue. Collegium touted one of the first deals as value based, although details were skimpy.
regards
ed at pharmalot
And so OPDP is ‘on the board’ for 2018 with 1 letter posted. Will it exceed last year’s total of 5 letters posted (although we didn’t see the fifth until we were weeks into 2018.)